RecallHawk
Class II Recall

MiniMed 740G Insulin Pump (MMT-1811, MMT-1812, MMT-1861, MMT-1862)

Medtronic MiniMed, Inc.

Summary

The FDA issued a Class II for MiniMed 740G Insulin Pump (MMT-1811, MMT-1812, MMT-1861, MMT-1862) by Medtronic MiniMed, Inc.. Reason: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-deliver.

Details

Source

Device Recall

External ID

Z-1746-2026

Action Date

2026-04-08

Status

Ongoing

Category

device

Product Description

MiniMed 740G Insulin Pump (MMT-1811, MMT-1812, MMT-1861, MMT-1862)

Lot/Code Info: Pump: UDI-DI(GTIN): User Guide Name(Part-Version): MiniMed 740G Insulin Pump: 763000504908, 763000504915, 763000505073, 763000484637, 763000505042, 763000504861, 763000629984, 763000504946, 763000504878, 763000559557, 763000504960, 763000505080, 763000505066, 763000629991, 763000505004, 763000504922, 763000504892, 763000505059, 763000504977, 763000505028, 763000505172, 763000505127, 763000505134, 763000505158, 763000505141, 763000505103, 763000505110, 763000504991, 763000505165, 763000504939, 763000504953, 763000504984, 763000505189, 763000851224, 763000851217, 763000769451, 763000769468: MINIMED 740G SYSTEM USER GUIDE mg/dL(M000149C002 1, M000149C004 1, M000149C005 1, M000150C005 1, M000150C002 1, M000150C021 2, M000149C016 1, M000149C021 1, M000150C004 1, M000150C025 1, M000150C030 1, M000149C014 1, M000149C006 1, M000150C003 1, M000150C015 1, M000150C028 1, M000150C018 1, M000150C022 1, M000150C007 1, M000149C017 1, M000149C008 1, M000150C008 1, M000150C032 1, M000150C029 1, M000150C012 1, M000150C016 1, M000150C010 1, M000149C011 1, M046726C001 3, M046726C002 3, M000149C020 1, M000149C025 1, M000150C024 1, M000150C023 1, M000150C013 1).

Quantity Affected: 24,946

Reason for Recall

All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.

Distribution

Worldwide - US Nationwide distribution including in the states of OR, CA, AZ, NY,TX,FL, OH, MO, TN,NJ, NC, SC, IL, VA, WA, DC, GA, PA, MS,IA, MI, NH, OK, SD, MT, WI, WV, MA, LA, MN, RI, AR, ME, AL, IN, UT, KY, CO, ND, MD, CT, NM, KS, ID, NV, DE, NE, VT, AK, HI, WY, PR, VI and the countries of Taiwan, New Zealand, Australia, Bangladesh, Brunei Darussalam, Cambodia, Indonesia, Malaysia, Maldives, Philippines, Thailand, Vietnam, Singapore, Pakistan, Hong Kong, China, Argentina, Aruba, Barbados, Bermuda, Bolivia, Plurinational State Of, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Panama, Paraguay, Peru, Puerto Rico, Trinidad And Tobago, Uruguay, Venezuela, Canada, South Korea, India, Albania, Algeria, Andorra, Armenia, Austria, Azerbaijan, Bahrain, Belarus, Belgium, Bosnia And Herzegovina, Botswana, Bulgaria, Canary Islands, Croatia, Cyprus, Czech Republic, Denmark, Egypt, Estonia, Faroe Islands, Finland, France, French Guyana, French Polynes., Georgia, Germany, Gibraltar, Greece, Guadeloupe, Hungary, Iceland, Iran, Iraq, Ireland, Israel, Italy, Jordan, Kazakhstan, Kenya, Kosovo, Kuwait, Kyrgyzstan, Latvia, Lebanon, Libya, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malawi, Malta, Martinique, Mauritius, Mayotte, Moldavia, Montenegro, Morocco, Namibia, Netherlands, New Caledonia, Nigeria, Northern Ireland, Norway, Oman, Poland, Portugal, Qatar, Reunion, Romania, Russia, San Marino, Saudi Arabia, Serbia, Sierra Leone, Slovakia, Slovenia, South Africa, Spain, St.Pier,Miquel., Sudan, Sweden, Switzerland, Syrian Arab Republic, Tanzania, Tunisia, Turkey, Turkmenistan, Ukraine, United Arab Emirates, United Kingdom, Uzbekistan, Yemen, Zambia, Zimbabwe.

Type: Voluntary: Firm initiated

Recall Initiated: 2026-02-13

Company

Context & Analysis

This is a Class II recall. Class II recalls indicate that use of or exposure to the product may cause temporary or medically reversible health consequences, or that the probability of serious consequences is remote.

This was one of 252 device recalls issued in the same week, part of 403 device-related FDA actions this month.

Medtronic MiniMed, Inc. has 43 FDA actions in our database, including 37 recalls and 6 clearances.

Frequently Asked Questions

What is a Class II recall?

A Class II recall means the product may cause temporary or medically reversible adverse health consequences, or the probability of serious adverse consequences is remote. Consumers should discontinue use.

What should I do if I have this product?

Stop using the product. Check the product against the specific lot numbers or identifiers listed in the recall. Contact the manufacturer (Medtronic MiniMed, Inc.) or your retailer for a refund or replacement. If you experienced adverse effects, report them to the FDA via MedWatch.

How often does Medtronic MiniMed, Inc. have FDA actions?

Medtronic MiniMed, Inc. has 43 FDA actions in our database, including 37 recalls and 6 device clearances.

Where can I find the official FDA record?

The official record is available on FDA.gov. Search for "Z-1746-2026" on FDA.gov for the full record. You can also use the openFDA API to query this record programmatically.

Want to know the moment something like this happens?

Get alerts for device

Related Actions